



## Sweetlife Flora Biotech

### Capital Raise Terms Summary

#### Commercial Houseplant Tissue Culture & Greenhouse Production Platform

##### Purpose of This Document

This document provides a high-level, non-binding summary of the proposed capital raise for Sweetlife Flora Biotech. It is intended to facilitate investor discussions and does not constitute a formal offer or commitment.

Final terms are subject to negotiation, documentation, and mutual agreement.

##### Offering Overview

**Issuer:** Sweetlife Flora Inc. (Biotech Division)

**Capital Sought:** \$1,000,000 CAD

**Use of Proceeds:**

Establishment and commissioning of a commercial-scale, vertically integrated houseplant tissue culture and greenhouse finishing platform, as detailed in the **Use of Funds** document.

**Stage:**

Production capability activation (non-R&D, non-real estate)

##### Proposed Investment Structure (Flexible)

The issuer is open to the following structures, depending on investor preference and alignment:

- Equity financing
- Convertible debenture / SAFE-style instrument
- Strategic minority investment

The objective is to align long-term incentives while preserving operational focus during platform activation.

## Valuation Approach

Valuation to be determined through investor discussion, informed by:

- production infrastructure value
- capital efficiency of the build-out
- near-term revenue activation
- strategic positioning as a Canada-first capability

The issuer is not anchoring to a fixed pre-money valuation at this stage in order to remain flexible and investor aligned.

## Minimum Investment

**Target Minimum Cheque Size:** To be determined based on investor profile and structure (anticipated to favor fewer, strategic investors)

## Expected Use of Capital Timeline

1. Capital deployment begins immediately upon close
2. Production commissioning initiated within the first 60 days
3. Initial commercial output targeted within 3–5 months
4. Stabilized production expected within 8 months

(Refer to **Production Activation Timeline** document)

## Investor Return Profile (Indicative)

Investor returns are expected to be driven by:

- margin-positive production economics
- increasing throughput and capacity utilization
- expansion of downstream monetization channels
- potential platform replication or strategic partnerships

This raise is focused on building foundational infrastructure, not short-term yield extraction.

## Governance & Reporting

Investors can expect:

- regular operational and financial reporting
- transparency on production metrics and milestones
- governance rights commensurate with investment size and structure

Specific rights to be defined in definitive agreements.

## **Exit Considerations (Illustrative)**

Potential long-term outcomes include:

- strategic acquisition by large-scale growers, distributors, or plant brands
- platform expansion and recapitalization
- continued operation as a cash-generating production asset

No specific exit timeline is being marketed.

## **Confidentiality & Disclaimer**

This summary is confidential and intended solely for prospective investors evaluating a potential investment in Sweetlife Flora Biotech.

This document does not constitute an offer to sell or a solicitation to buy securities. Any offering will be made only pursuant to definitive agreements and in compliance with applicable securities laws.